R

Radiopharm Theranostics Ltd
ASX:RAD

Watchlist Manager
Radiopharm Theranostics Ltd
ASX:RAD
Watchlist
Price: 0.029 AUD 61.11% Market Closed
Market Cap: 80.6m AUD

Radiopharm Theranostics Ltd
Income to Minority Interest

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Radiopharm Theranostics Ltd
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
R
Radiopharm Theranostics Ltd
ASX:RAD
Income to Minority Interest
AU$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Income to Minority Interest
-$134m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Income to Minority Interest
AU$708.5k
CAGR 3-Years
18%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

Radiopharm Theranostics Ltd
Glance View

Market Cap
80.6m AUD
Industry
Biotechnology

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.

RAD Intrinsic Value
0.255 AUD
Undervaluation 89%
Intrinsic Value
Price
R

See Also

What is Radiopharm Theranostics Ltd's Income to Minority Interest?
Income to Minority Interest
1.6m AUD

Based on the financial report for Jun 30, 2025, Radiopharm Theranostics Ltd's Income to Minority Interest amounts to 1.6m AUD.

Back to Top